Abstract Molecular subtypes of glioblastoma (GBM) with distinct alterations have been identified. There is need for reproducible, versatile preclinical models that resemble specific GBM phenotypes to facilitate preclinical testing of novel therapies. We present a cell line-based murine proneural GBM model and characterize its response to radiation therapy. Proneural gliomas were generated by injecting PDGF-IRES-Cre retrovirus into the subcortical white matter of adult mice that harbor floxed tumor suppressors (Pten and p53) and stop-floxed reporters. Primary cell cultures were generated from the retrovirus induced tumors and maintained in vitro for multiple passages. RNA sequencing-based expression profiling of the resulting cell lines was performed. The tumorigenic potential of the cells was assessed by intracranial injection into adult naïve mice from different strains. Tumor growth was assessed by bioluminescence imaging (BLI). BLI for tumor cells and brain slices were obtained and compared to in vivo BLI. Response to whole-brain radiation was assessed in glioma-bearing animals. Intracranial injection of Pdgf 
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? glioma cells led to formation of GBM-like tumors with 100 % efficiency (n = 48) and tumorigenesis was retained for more than 3 generations. The cell lines specifically resembled proneural GBM based on expression profiling by RNA-Seq. Pdgf 
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Introduction
A great deal of the research in glioblastoma (GBM) relies on cell lines artificially selected to grow in vitro, which presents issues for use as tumor models. First, the genetic profile of passaged cell lines does not fully reflect that seen in human gliomas [1, 2] . Also, many of these cell lines give rise to tumors that do not resemble human gliomas histologically [3] . Consequently, pre-clinical results often do not translate accurately to clinical trials and practice. The search for better glioma models is necessary for advancing the field of neurooncology. Moreover, a pre-clinical, cell line-based model that allows for in vitro as well as in vivo studies would allow for efficient and comprehensive testing of experimental therapies.
Glioblastoma has been classified into four categories based on expression-based profiling: proneural, neural, mesenchymal and classical [4] . Proneural GBM, which includes most of secondary GBM and a distinct subset of primary GBM, is characterized by p53, IDH1/2 mutations and PDGFR amplifications [4] [5] [6] . Recently, our group generated a transgenic mouse glioma model with a proneural phenotype by transforming white matter glial progenitors in vivo. Genome-wide expression analyses and cross-species comparisons with the TCGA data revealed that the mouse tumors most resembled the proneural subtype of GBM and that both mouse and human proneural gliomas were significantly enriched for genes expressed by oligodendrocyte progenitor cells (OPC) [7] . Here, we show that cells isolated from these tumors can be cultured for multiple passages while retaining their proneural phenotype and their capacity to generate tumors that recapitulate GBM. These mouse glioma cells express luciferase and therefore, tumor growth and response to therapy can be followed by luciferase-based bioluminescence imaging (BLI). We describe the effects achieved by radiotherapy, a standard of care for human GBM. This model is a versatile tool to evaluate novel adjuvant therapies for proneural GBM.
Methods
Retrovirus production and injections A 0.8 kb fragment encoding PDGF-B-hemagglutinin (HA) [8] was ligated into the MCS1 region and Cre was ligated into the MCS2 region of the retroviral vectors pQCXIX. Using these constructs, replication-deficient viruses with vsv-G coats were generated as previously described [9] . Viral titers were established in colony-forming units (CFU) by incubating YFP _stop-lox mouse embryonic fibroblasts with serial dilutions of retrovirus in tenfold steps. At 48 h, the number YFP cell clusters were counted. This number was multiplied by the dilution factor in order to determine the CFU. Virus was then injected into the subcortical white matter (stereotactic coordinates relative to bregma: 2.1 mm lateral, 2.1 mm rostral, 1.8 mm deep) of adult Pten ox/lox / p53 lox/lox /luciferasestop-lox transgenic mice using a Hamilton syringe with a 33 gauge needle (0.4 ll at 0.2 ll/min) [7] . These mice have been backcrossed B6(Cg)-Tyr c-2J /J, or B6-albino mice, for more than 10 generations, resulting in white mice that are suitable for BLI.
Tumor cell isolation and injection
All mice developed tumors with retrovirus injection. Following IACUC guidelines, animals were sacrificed at the first sign of morbidity. Ex-vivo gross total resection of the tumor was performed and tumor cells were isolated using enzymatic digestion [10, 11] . The isolated cells were cultured for up to 15 passages in a 2:1 ratio of basal media (DMEM, N2, T3, 0.5 % FBS, and penicillin/streptomycin/amphotericin) in B104 conditioned media [5] . This media was further supplemented with PDGF-AA (Sigma-Aldrich; St. Louis, MO) and FGFb (Gibco; Grand Island, NY, USA) to a concentration of 10 ng/ml. Intracranial injection of the freshly prepared tumor cells was performed as previously described for the retrovirus. 4 Pdgf ? Pten -/-p53 -/-tumor cells isolated from two different primary tumors (Cohort 1 n = 12, Cohort 2 n = 6) and were observed daily and sacrificed at first signs of morbidity, including weight loss, seizures, and hemorrhage. A parallel study was performed in FvB backround mice injected with 2.0 9 10 4 Pdgf ? Pten -/-p53 -/-tumor cells. Brains were either fixed in 4 % paraformaldehyde and examined histologically or were prepared for culture and transplant into naïve mice using the conditions previously described.
Bioluminescence imaging of cellular suspensions of digested tumors Tumor cells were plated at different cell densities in a 24-well plate; 3.0 9 10 3 , 3.0 9 10 4 , and 3.0 9 10 5 cells per well, each in triplicate. 300 ll of a 0.30 mg/ml solution of D-Luciferin (Fisher Scientific, Waltham, MA) was added to each well and luminescence was measured using the Xenogen IVIS 200 using Living Image 3.2 (Xenogen; Hopkinton, MA, USA) after 10 min.
Bioluminescence imaging of in vivo tumor burden
Mice injected with tumor cells were anesthetized with 2.5 % isofluorane and injected intraperitoneally with 3 mg of D-Luciferin. BLI was performed 10 min after injection with a region of interest (2.25 cm) centered upon the mouse's head.
Bioluminescence imaging of ex vivo brain slices
Mice to undergo the ex vivo imaging were euthanized following the final in vivo image acquisition. The brain was removed and sectioned into 1.0 mm thick slices. Each slice was placed in a 1 cm well containing PBS. 300 ll of a 0.30 mg/ml solution of D-luciferin was added to each well and incubated for 10 min before BLI was measured. The sum BLI of the slices represented the ex vivo total. This was compared to the in vitro and in vivo BLI using linear regression (Microsoft Excel).
In vivo radiation treatment
Mice were imaged on the 6th day following injection of 2.0 9 10 4 tumor cells and randomly assigned to treatment groups (n = 24). Radiation was delivered with a Mark 1 Cesium-137 irradiator (JL Shepherd and Associates; San Fernando, CA) at 6 Gy per day for 10 days. Each individual mouse placed behind a 1.4 cm lead barrier designed to target the head. Treatment took place on 6-10 dpi and 13-17 dpi, with holidays on days 11 and 12.
Immunohistochemistry and microscopy Brains for immunohistochemistry were fixed by cardiac perfusion with 4 % paraformaldehyde. Hematoxylin and eosin stains and immunoperoxidase stains were performed using the following antibodies: anti-Olig2 (1:500; Chemicon; Temecula, CA, USA), anti-GFAP (1:1000; Chemicon; Temecula, CA), anti-Ki67 (1:1000, Vector, Burlingame, CA), and anti-PDGFR a (1:500; Cell Signaling, Beverly, MA, USA). Stained sections were examined and photographed using a fluorescent microscope (Zeiss; Oberkochen, Germany) and analyzed with Metamorph (Molecular Devices; Sunnyvale, CA, USA).
RNA-Seq based classification of tumor cell line and identification of proneural subtype
We measured genome-wide expression profiles of three mouse tumor cell lines and four virus-induced mouse tumors by RNA-Seq. For each sample, we obtained 15-30 million single-end, 100-base reads on an Illumina HiSeq 2000 sequencer. We rank-ordered the expression levels of the GBM subtype classifier genes obtained from RNA sequencing of our tumor and cell line samples. We then rank-ordered the expression levels of these same genes in the 202 TCGA human microarray data sets for which GBM subtype information is available [4] . For each tumor and cell line RNA-Seq data set, we calculated the Spearman's rank correlation coefficient with each subtyped human microarray data set. This provides an estimate of statistical dependence between the mouse tumor and cell line expression profiles and those of human samples from each of the four GBM subtypes without assumptions about the functional relationship between microarray expression levels and those obtained by RNA-Seq. We use the median value of the correlation between an RNA-Seq data set and the TCGA microarray data for a given subtype as a similarity score for that subtype.
To validate this approach, we used the same correlation calculation to classify the small number of available subtyped TCGA samples that have corresponding RNA-Seq data sets. Our method correctly classified 7/8 proneural samples, 8/10 Mesenchymal samples, and 5/5 Classical samples. In cases where the incorrect subtype was identified, the correct subtype was consistently the second most similar subtype. However, the neural subtype was more ambiguous, and only 2/7 Neural samples were called correctly.
Results
Pdgf
? Pten -/-p53 -/-luciferase ? cells form murine glioblastomas and resemble the proneural phenotype
Injection of Pdgf
? Pten -/-p53 -/-luciferase ? glioma cells led to formation of GBM-like tumors with 100 % efficiency for tumor cells passaged for up to 15 generations. Furthermore, these cells retained tumor-forming capacity over at least three generations of serial intracranial transplantation. This is similar to what was seen following intracranial injection of freshly isolated cells into NOD/ SCID mice [7] . Comparison of the subtype-specific genes based on level of expression of the mouse cell line (n = 3) and virus-induced tumors (n = 4) by RNA-Seq to ordered classifier gene sets in the TCGA yielded the strongest correlation with the proneural subtype (Fig. 1) [4] (source data available download at GEO at http://www.ncbi.nlm. nih.gov/geo/; Reference number: GSE45031). This observation is summarized (Table 1) , which shows the median Spearman's rank correlation coefficients between expression profiles of the four mouse tumors or three mouse cell lines and the subtyped human GBM expression profiles from the TCGA (http://cancergenome.nih.gov/) (n = 202).
The tumors recapitulated histological features of human GBM, including glomeruloid vascular proliferation, pseudopalisading necrosis, and diffusely infiltrative edges (Fig. 2a) . Immunohistochemical stains showed the majority of tumor cells strongly positive for Pdgfr alpha and Olig-2, while Gfap staining was seen predominantly in astrocytes distributed throughout the tumor (Fig. 2b-d) , These results are consistent with the pattern of staining seen in the initial, virus induced tumors [7] .
Bioluminescence correlates with glioma size and localization and predicts onset of tumor-related morbidity Luciferase expression enabled the reporting of growth dynamics and response to treatments in our cell lines and corresponding brain tumors. In vitro, luminescence correlated with number of Pdgf ? Pten -/-p53 -/-luciferase ??
glioma cells (Fig. 3a) . Next, we compared the in vivo luminescence of these tumors with the sum, ex vivo luminescence of brain serially sectioned. On average, the in vivo luminescence was 4.4 times lower than the sum luminescence of the slices, presumably from the quenching of signal by overlying tissue. Nevertheless, there was a direct correlation between in vivo and ex vivo luminescence, observed in small and large tumors (Fig. 3b) . Moreover, luminescence distribution co-localized with the anatomic locations of the tumors (Fig. 3c) . Thus, in vivo luminescence quantitatively follows tumor size and growth dynamics. Furthermore, luminescence was predictive of morbidity and mortality. 93 % morbidity was seen during a 5-day period following a luminescence measurement between 1 9 10 8 and 5 9 10 8 photons/s cm 2 (Fig. 4) .
Cell-based Pdgf
? Pten -/-p53 -/-luciferase ? gliomas show reproducible growth dynamics and are susceptible to radiotherapy Two separate cell lines isolated from different primary tumors underwent 6 passages and then assessed in vivo following intracranial injection. BLI, as a surrogate for growth dynamics and tumor burden, and survival (27 vs. 29 days, log rank p = 0.35) were indistinguishable between the two cohorts ( Supplementary Figure) .
To evaluate whether Pdgf ? Pten -/-p53 -/-cells can engraft in different strains, a similar experiment with equal number of cells (2 9 10 4 cells) was performed on mice from FvB strain (n = 7). There was 100 % tumor penetrance. Whereas there were no significant differences in tumor growth kinetics, as measured by BLI, a modest but significant increase in survival was noticed for the FvB group compared to survival data when cells were injected Fig. 1 Histograms showing the Spearman's rank correlation coefficients between human GBM expression profiles from the TCGA for samples representing each of the four GBM subtypes in the TCGA data (proneural n = 57, neural n = 33, classical n = 54, mesenchymal n = 58) and a mouse tumor (averaged over four samples) and b mouse cell line (averaged over three samples) RNASeq profiles. Both the mouse tumors and cell lines, are most similar to the proneural subtype of human GBM into Pten lox/lox /p53 lox/lox /luciferasestop-lox mice that are syngeneic to the cell line (cohorts 1 and 2) (log rank p \ 0.05) (Supplementary Figure) .
Response to radiation demonstrates utility of this model for assessing therapies. BLI was decreased for radiated versus control mice at 22 and 24 dpi (p \ 0.05) (Fig. 5a ). Though this difference was lost over time, a modest but significant increase in survival was noted (33 days in treated vs. 27 days in controls, p = 0.0055) (Fig. 5b) . These findings are similar to our previous work using cells that were freshly isolated from the retrovirus induced tumors [12] , demonstrating the therapeutic responsiveness of these cell lines remains consistent over multiple passages and across separate tumor preparations.
Discussion
Distinguishing promising cancer treatments that merit clinical testing and defining the molecular characteristics of the patients that will benefit from these treatments are formidable challenges. Overcoming this issue is key for development of effective therapies for GBM, for which distinct molecular subgroups exist [4] . We present a mouse model of proneural GBM that consists on Pdgf ? Pten -/-p53 -/-luciferase ? glioma cells. We characterize this cellbased model, and show its features as a convenient and relevant model for pre-clinical testing. To illustrate its utility, we tested the response to radiation therapy, a major component of the standard of care for this disease.
This cell-based model combines the advantages of the genetically engineered and retrovirus-based tumor models. Tumors are generated with well-defined genetic alterations (Pdgf pathway activation, p53 and Pten loss of function) commonly seen on human GBM. Moreover, this model offers the possibility of genetic manipulation and experimentation in vitro as well as in vivo. Furthermore, this model accurately recapitulates the histopathologic hallmarks of GBM including pseudopalisading necrosis, diffuse infiltration, and vascular proliferation. These histological characteristics contrast sharply with human xenografts from traditional established cell lines still in use [13] [14] [15] , which tend to grow as dense clusters of tumor cells with little invasion. Alternative cell-based glioma models with a more realistic histological profile are available, but are usually based on human glioma cell preparations requiring immunocompromised rodent hosts for in vivo experiments [15] . This issue might potentially give rise to artificial cross species microenvironment interactions between host and tumor cells, and limit the study of tumor immunology. An alternative to the cell line models include retrovirus/transgenic mouse gliomas systems [7, 8] , which are powerful models, but involve transgenic mouse and virus-related resources that may not be available to some researchers. The use of cell lines generated from retrovirus/transgenic mouse models provides a convenient and accessible alternative, and offer the possibility of in vitro analyses to compliment the in vivo studies.
Another strength of this cell-based system is the ability for non-invasive quantification of tumor growth by BLI, which may represent a more sensitive indicator of response to therapy than overall survival. Furthermore, serial Fig. 4 Luminescence is predictive of mortality, with bioluminescence between 1.0 9 10 8 and 5.0 9 10 8 photons/s cm 2 being associated with a 93 % risk of death in 5 days luciferase imaging allows for longitudinal monitoring of tumor growth dynamics in the setting of therapies and may be useful for evaluating treatments and their combinations. Using this approach, wide ranges of anti-tumor therapies can be screened in vitro using this cell line before pursuing more costly in vivo experiments, either in retrovirus or cell line-based tumors.
In this study, we have demonstrated that Pdgf ? Pten -/-p53 -/-cell lines specifically resemble the gene expression profile of human proneural GBM. The cell lines analyzed were expanded over 6 passages in culture and retained the proneural phenotype. Silber et al. [16] and Schulte et al. [17] have recently reported human glioma cell lines that retain a proneural expression profile while grown in vitro in serum free media. Our cell-based model is a good complement to these lines as given its murine origin, it allows their implantation into immunocompetent hosts.
We present a murine proneural GBM model with genetic and histological resemblance to human proneural GBM and show a modest response to radiation therapy. For these reasons, we offer this convenient glioma cell line model to the neurooncology research community as a tool to evaluate novel treatments for this devastating disease. In future studies, it will be important to identify the genetic and epigenetic alterations that accumulate in this model, and characterize how they relate to alterations that occur in the different types of human proneural gliomas [18, 19] .
